Form 4: Tevogen Bio CEO Ryan Saadi Receives Significant Restricted Stock Grant with Long-Term Vesting

Tevogen Bio Holdings Inc. CEO Ryan H. Saadi was granted 8,000,000 shares of common stock as restricted stock, set to vest in annual installments beginning in 2032.

Summary

• Ryan H. Saadi, Chief Executive Officer, Director, and 10% Owner of Tevogen Bio Holdings Inc. (TVGN), was granted 8,000,000 shares of common stock.
• The transaction date for this acquisition was June 27, 2025, with a price of $0 per share, indicating a grant.
• The shares represent a grant of restricted stock under the Tevogen Bio Holdings Inc. 2024 Omnibus Incentive Plan.
• The restricted stock will vest ratably in four equal annual installments, commencing on June 27, 2032.
• Vesting is contingent upon Mr. Saadi remaining in service with the Issuer at the specified vesting dates.
• Following this transaction, Mr. Saadi directly beneficially owns 124,814,453.322 shares of common stock and indirectly owns 193,924 shares through his wife.

Sentiment

Score: 7

Explanation: The grant of a significant number of shares to the CEO is generally positive for aligning management and shareholder interests. However, the very long vesting period and the unusual future transaction date introduce some complexity.

Positives

• The grant of 8,000,000 shares of restricted stock aligns the CEO's long-term interests with those of the shareholders, incentivizing sustained performance.
• The significant size of the grant demonstrates a strong commitment from the company to its CEO and potentially reflects confidence in future growth.

Negatives

• The vesting schedule for the restricted stock is exceptionally long, with the first installment not commencing until June 27, 2032, which is seven years after the transaction date.
• The transaction date of June 27, 2025, and the signature date of July 1, 2025, are in the future, which is unusual for a Form 4 filing that typically reports past transactions.

Future Outlook

The grant of restricted stock with a vesting period extending to 2032 indicates a long-term strategic outlook and a desire to retain key executive talent for an extended period.

Industry Context

This Form 4 filing details an insider transaction, which is a routine disclosure for publicly traded companies. It reflects a specific compensation event for a key executive rather than a broader industry trend.

Corporate Governance

Related Party Transactions

• The transaction involves the grant of shares to the Chief Executive Officer, who is also a Director and 10% owner, classifying it as an insider transaction and a related party dealing.

Stakeholder Impact

• Shareholders: The grant could be viewed positively as it aligns the CEO's long-term interests with shareholder value, but it also represents potential future dilution as shares vest.
• Employees: The CEO's long-term commitment, as implied by the vesting schedule, may signal stability and long-term vision for the company's workforce.

Next Steps

• The restricted stock will begin to vest in four equal annual installments starting on June 27, 2032, contingent on the CEO's continued service.

Key Dates

Keywords

Tevogen Bio Holdings Inc., TVGN, Ryan H. Saadi, CEO, restricted stock, stock grant, insider transaction, equity compensation, Form 4, executive compensation, incentive plan